Background:This is a randomized, superiority, double blind, placebo-controlled, multicenter study comparing evolocumab 420mgSC vs. placebo administered in the acute phase of ACS. The aim is to evaluate the effectiveness of the PCSK9 inhibitorevolocumab as compared with placebo for reduction of LDL-C levels within 8 weeks in patients receiving guideline-recommended high-intensity statin treatment (atorvastatin 40mg QD). Sponsor: Inselspital Bern, Prof. Dr. Stephan WindeckerTrial Registration No:NCT03287609 (clinicaltrials.gov) LinkTrial Status:recruitingEnrolling Centers:Bern, Basel, Fribourg, Genf, Lausanne, Lugano, ZürichCore Study Team: